CannTrust Holdings Inc (TSE:TRST) (NYSE:CTST) (FRA:C9S) announced pricing of its previously-announced underwritten public offering today. Much to the surprise of investors, it didn’t materialize at 10-Day VWAP (over $7.10/share), rather, at a price that was that was significant below.
CannTrust’s offering of 36,363,636 common shares came at a price of $5.50USD. The company is selling 30,909,091 common shares in the offering for total gross proceeds of approximately US$170 million—with another 5,454,545 common shares offered separately. The underwriters have a 30-day option to purchase up to an additional 4,636,363 and 818,182 common shares, respectively, at the public offering price, less the underwriting discount.
The Company intends to use the net proceeds of the offering for general corporate purposes, international expansion, enhanced extraction capacity, upgrades for GMP Certification and biosynthesis development.
BofA Merrill Lynch, Citigroup, Credit Suisse Securities (USA) LLC and RBC Capital Markets are acting as lead book-running managers for the offering. Jefferies LLC and Canaccord Genuity LLC are also acting as book-running managers.
While the pricing of the offering is coming at a steep discount, it’s important to note there are no warrants attached to the offer; common is such transactions. Without these potential “sweetner” convertibles to attract investors, there was less incentive to purchase securities at prices closer to its recent median. This, despite the common tumbling ↓35.85% since March 27th—the day before the company issued Q4 2018 financial results. Currently shares are lower be another ↓10.09%, trading $0.29 above its public offering price.
Whether CannTrust’s sour undertones have affected the market broader today is unclear. Certainly, such low ball pricing—where investors demand a deep discount to participate—isn’t exactly a confidence booster for the sector. The Horizons Marijuana Life Sciences Index ETF is lower by ↓2.86%, with several Tier-1 and mid-major licensed producers taking it on the chin.
Midas Letter will have further coverage as events warrant.
Midas Letter is provided as a source of information only, and is in no way to be construed as investment advice. James West, the author and publisher of the Midas Letter, is not authorized to provide investor advice, and provides this information only to readers who are interested in knowing what he is investing in and how he reaches such decisions.
Investing in emerging public companies involves a high degree of risk and investors in such companies could lose all their money. Always consult a duly accredited investment professional in your jurisdiction prior to making any investment decision.
Midas Letter occasionally accepts fees for advertising and sponsorship from public companies featured on this site. James West and/or Midas Letter may also receive compensation from companies affiliated with companies featured on this site. James West and/or Midas Letter also invests in companies on this site and so readers should view all information on this site as biased.